share_log

Insmed | 10-Q: Q3 2024 Earnings Report

Insmed | 10-Q: Q3 2024 Earnings Report

Insmed | 10-Q:2024財年三季報
美股SEC公告 ·  2024/10/31 11:05

牛牛AI助理已提取核心訊息

Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed在2024年第三季度報告了強勁的財務業績,總營業收入同比增長18.2%,達到9340萬美金,相較於2023年第三季度的7910萬美金。增長主要受到ARIKAYCE在所有地區銷售擴展的推動,美國營業收入增長12.9%,達到6690萬美金,日本營業收入增長30.9%,達到2100萬美金,歐洲營業收入增長45.3%,達到560萬美金。研究和開發費用從2023年第三季度的10910萬美金增加到15080萬美金,主要是由於製造業成本的增加和員工人數的增加。SG&A費用從9060萬美金上升至11890萬美金,主要由於人員成本和brensocatib的商業準備活動增加。公司報告淨虧損爲22050...展開全部
Insmed在2024年第三季度報告了強勁的財務業績,總營業收入同比增長18.2%,達到9340萬美金,相較於2023年第三季度的7910萬美金。增長主要受到ARIKAYCE在所有地區銷售擴展的推動,美國營業收入增長12.9%,達到6690萬美金,日本營業收入增長30.9%,達到2100萬美金,歐洲營業收入增長45.3%,達到560萬美金。研究和開發費用從2023年第三季度的10910萬美金增加到15080萬美金,主要是由於製造業成本的增加和員工人數的增加。SG&A費用從9060萬美金上升至11890萬美金,主要由於人員成本和brensocatib的商業準備活動增加。公司報告淨虧損爲22050萬美金,相較於2023年第三季度的15890萬美金。截至2024年9月30日,公司保持了強大的財務狀況,現金及現金等價物爲46150萬美金,加上10億美金的可交易證券。Insmed仍按計劃在2024年第四季度提交brensocatib在支氣管擴張症的NDA,因其積極的Aspen三期試驗結果。公司還關閉了對ARIKAYCE的ENCORE研究的篩選,預計將在2026年第一季度公佈頂線數據。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 285

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。